Surmontil
Surmontil Overview
Trimipramine is a prescription medication used to treat depression. Trimipramine belongs to a group of drugs called tricyclic antidepressants, which work by increasing the amount of certain natural substances in the brain that are needed to maintain mental balance.
This medication comes in capsule form and is typically taken once or multiple times a day, with or without food.
Common side effects of trimipramine include nausea, vomiting, headache, or dizziness. Do not drive or operate heavy machinery until you know how trimipramine affects you.
How was your experience with Surmontil?
Uses of Surmontil
Trimipramine is a prescription medication used to treat depression.
This medication may be prescribed for other uses. Ask your doctor or pharmacist for more information.
Manufacturer
Generic
Trimipramine
For more information on this medication choose from the list of selections below.
Surmontil Drug Class
Surmontil is part of the drug class:
Side Effects of Surmontil
Serious side effects have been reported with trimipramine. See the “Drug Precautions” section.
Common side effects of trimipramine include the following:
- nausea
- vomiting
- insomnia
- dizziness
- anxiety
This is not a complete list of trimipramine side effects. Ask your doctor or pharmacist for more information.
Tell your doctor if you have any side effect that bothers you or that does not go away.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
Surmontil FDA Warning
Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of trimipramine maleate or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Trimipramine maleate is not approved for use in pediatric patients.